Open AccessLong-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients
Author(s) -
Nuh Ataş,
G Eroğlu,
Hulya Nur Sodan,
Beyza Olcay Öztürk,
Hakan Babaoğlu,
Hasan Satış,
Hazan Karadeniz,
Aslıhan Avanoğlu Güler,
Reyhan Bilici Salman,
Berna Göker,
Mehmet Akif Öztürk,
Şeminur Haznedaroğlu,
Abdurrahman Tufan
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/815tdt
Subject(s) - canakinumab , anakinra , medicine , familial mediterranean fever , discontinuation , tolerability , pediatrics , adverse effect , disease
Anakinra and canakinumab are the most commonly used agents in colchicine resistant/intolerant patients. In this study we investigated long-term efficacy and safety of anakinra and canakinumab.